The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
Aims Cachexia, the wasting disorder associated with a wide range of serious illnesses including cancer, is a major cause of morbidity and mortality. There is currently no widely approved therapeutic agent for treating or preventing cancer-associated cachexia. Colorectal cancer and nonsmall cell l...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Springer
2011
|
| 主題: | |
| オンライン･アクセス: | http://irep.iium.edu.my/18416/1/13539_2011_Article_46.pdf http://irep.iium.edu.my/18416/ http://dx.doi.org/10.1007/s13539-011-0046-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|